Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 over exp |
| Therapy | Ipilimumab |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 over exp | lung non-small cell carcinoma | predicted - sensitive | Ipilimumab | Clinical Study - Meta-analysis | Actionable | In a meta-analysis, treatment with immune checkpoint inhibitors including Tecentriq (atezolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), and Keytruda (pembrolizumab) resulted in improved progression-free survival (HR=0.41, p<0.001) and overall survival (HR=0.62, p=0.006) in non-small cell lung cancer patients with high CD274 (PD-L1) expression compared to patients with low CD274 (PD-L1) expression (PMID: 31290993). | 31290993 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (31290993) | Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. | Full reference... |